[Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
Salentijn
G J
GJ
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000191:economics* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D016595:Misoprostol / Q000191:economics / Q000627:therapeutic use; D009853:Omeprazole / Q000191:economics / Q000627:therapeutic use; D013272:Stomach Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000191:economics*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D016595:Misoprostol; D009853:Omeprazole
Effectiviteit, veiligheid en kosten van strategieën ter preventie van gastropathie door gebruik van niet-steroïde anti-inflammatoire geneesmiddelen.